Literature DB >> 6123838

Monoclonal antibodies specific for the Sabin vaccine strain of poliovirus 3.

M Ferguson, Q Yi-hua, P D Minor, D I Magrath, M Spitz, G C Schild.   

Abstract

Monoclonal antibodies to poliovirus type 3 secreted by nine mouse hybridoma cell lines were tested for virus-strain specificity with a collection of wild and vaccine-like type 3 viruses, the genetic characteristics of which had been determined by T1-oligonucleotide mapping. Four of the monoclonal antibodies had both virus-neutralising and antigen-blocking activity, and five had antigen-blocking activity only. Of the four virus-neutralising antibodies, two (NIBp138, NIBp165) reacted only with Sabin vaccine virus and other poliovirus type 3 strains with Sabin-like T1-oligonucleotide maps. Two antibodies (NIBp132, NIBp134) neutralised a broad range of type 3 viruses. Of five monoclonal antibodies with antigen-blocking activity only, four (NIBp135, NIBp136, NIBp140, and NIBp141) reacted exclusively with Sabin virus and strains with Sabin-like maps, and one (NIBp139) reacted with all type 3 strains tested. The vaccine-specific monoclonal antibodies, particularly NIBp138 and NIBp165, have considerable potential value in distinguishing wild type 3 viruses from those of Sabin vaccine origin. This conclusion was strongly supported by the finding that certain viruses which showed genetic evidence of being related to Sabin virus reacted well with vaccine-specific monoclonal antibodies despite having undergone genetic drift away from vaccine virus as indicated by changes in up to 30% of their oligonucleotides.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6123838     DOI: 10.1016/s0140-6736(82)91091-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  10 in total

Review 1.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

2.  Intertypic cross-reactions of nonneutralizing, monoclonal poliovirus antibodies.

Authors:  R Vrijsen; B Rombaut; A Boeye
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

3.  Functional basis of poliovirus neutralization determined with monospecific neutralizing antibodies.

Authors:  E A Emini; S Y Kao; A J Lewis; R Crainic; E Wimmer
Journal:  J Virol       Date:  1983-05       Impact factor: 5.103

4.  Genetic basis for immunological aberrations in poliovirus Sabin serotype 3 strains imported in the netherlands.

Authors:  J H Reimerink; H G van der Avoort; A M van Loon; M P Koopmans
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

5.  WHO collaborative study on the use of monoclonal antibodies for the intratypic differentiation of poliovirus strains.

Authors:  M Ferguson; D I Magrath; P D Minor; G C Schild
Journal:  Bull World Health Organ       Date:  1986       Impact factor: 9.408

6.  Identification of vaccine-related polioviruses by hybridization with specific RNA probes.

Authors:  L De; B Nottay; C F Yang; B P Holloway; M Pallansch; O Kew
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

7.  Natural variation of poliovirus neutralization epitopes.

Authors:  R Crainic; P Couillin; B Blondel; N Cabau; A Boué; F Horodniceanu
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

8.  Viruses in sewage waters during and after a poliomyelitis outbreak and subsequent nationwide oral poliovirus vaccination campaign in Finland.

Authors:  T Pöyry; M Stenvik; T Hovi
Journal:  Appl Environ Microbiol       Date:  1988-02       Impact factor: 4.792

Review 9.  The application of monoclonal antibodies in the study of viruses.

Authors:  M J Carter; V ter Meulen
Journal:  Adv Virus Res       Date:  1984       Impact factor: 9.937

10.  Chapter 4 Picornavirus infections.

Authors: 
Journal:  Perspect Med Virol       Date:  2008-05-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.